CPRX - CATALYST PHARMACEUTICALS, INC.

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 19.6

Open

Bid

$ 19.59 x 200

Ask

$ 19.61 x 100

Day's Range

-- - --

52 Week Range

$ 11.55 - $ 20.87

Volume

736,447

Average Volume

Market Cap

2.33B

Beta (5Y Monthly)

$ 1.13

PE Ratio (TTM)

$ 34.14

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-08-2023	09-30-2023	10-Q
5	08-09-2023	06-30-2023	10-Q
6	05-10-2023	03-31-2023	10-Q
7	03-15-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q
11	03-16-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	03-15-2021	12-31-2020	10-K
16	11-09-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-11-2020	03-31-2020	10-Q
19	03-16-2020	12-31-2019	10-K
20	11-12-2019	09-30-2019	10-Q
21	08-07-2019	06-30-2019	10-Q
22	05-10-2019	03-31-2019	10-Q
23	03-18-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-14-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-09-2017	06-30-2017	10-Q
30	05-10-2017	03-31-2017	10-Q
31	03-15-2017	12-31-2016	10-K
32	11-09-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-10-2016	03-31-2016	10-Q
35	03-15-2016	12-31-2015	10-K
36	11-09-2015	09-30-2015	10-Q
37	08-10-2015	06-30-2015	10-Q
38	05-11-2015	03-31-2015	10-Q
39	03-13-2015	12-31-2014	10-K
40	11-13-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

top-3-health-care-stocks-that-may-crash-in-august

Top 3 Health Care Stocks That May Crash In...
08/14/2024 12:35:02

The Latest Analyst Ratings For Catalyst Ph...
08/12/2024 13:00:52

HC Wainwright & Co. Maintains Buy on Catal...
08/12/2024 10:39:43

HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price...

Citigroup Maintains Buy on Catalyst Pharma...
08/09/2024 22:42:43

Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target ...

Truist Securities Maintains Buy on Catalys...
08/09/2024 13:11:03

Truist Securities analyst Joon Lee maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target f...

Catalyst Pharmaceuticals Reaffirms 2024 To...
08/07/2024 21:12:30

Catalyst Pharmaceuticals Q2 2024 Adj. EPS ...
08/07/2024 20:52:01

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate...

top-3-health-care-stocks-you-may-want-to-dump-this-quarter

Top 3 Health Care Stocks You May Want To D...
07/30/2024 14:13:47

Catalyst Pharmaceuticals Enters Exclusive ...
07/24/2024 12:10:50

A Closer Look at 7 Analyst Recommendations...
06/03/2024 13:00:46

HC Wainwright & Co. Reiterates Buy on Cata...
06/03/2024 10:28:31

HC Wainwright & Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and maintains $26 p...

Catalyst Pharmaceuticals Announces FDA App...
05/30/2024 17:42:24

Decoding 8 Analyst Evaluations For Catalys...
05/10/2024 14:00:14

HC Wainwright & Co. Maintains Buy on Catal...
05/10/2024 12:11:53

HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price...

Catalyst Pharmaceuticals Reaffirms FY24 To...
05/08/2024 20:49:02

Reaffirm the 2024 full-year total revenue guidance in the range of $455 million and $475 million.

Catalyst Pharmaceuticals Q1 Adj $0.38 Beat...
05/08/2024 20:22:33

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate...

Decoding 7 Analyst Evaluations For Catalys...
03/27/2024 13:00:53

Oppenheimer Reiterates Outperform on Catal...
03/27/2024 11:32:44

Oppenheimer analyst Leland Gershell reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Outperform and maintains $29 pr...

Cantor Fitzgerald Reiterates Overweight on...
03/22/2024 18:00:39

Cantor Fitzgerald analyst Charles Duncan reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight and maintains $...

Cantor Fitzgerald Reiterates Overweight on...
03/14/2024 14:19:31

Cantor Fitzgerald analyst Charles Duncan reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight and maintains $...